Atossa Genetics Inc (ATOS NASDAQ) stock market data APIs
$5.1106
0.29(5.7%)
as of May 12, 2026
Try our APIs with
free plan!
Atossa Genetics Inc Financial Data Overview
Price chart is built with
Anychart
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Prev. Close
5.1106
Open
5.4046
High
5.4354
Low
5.0352
52 wk Range
3.76-19.35
Market Cap
47 363 K
Shares Outstanding
8 611 K
EPS
-1.11
Beta
1.245
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Atossa Genetics Inc data using free add-ons & libraries
Get Atossa Genetics Inc Fundamental Data
Atossa Genetics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -37 125 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-01
- EPS/Forecast: -0.0667
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Atossa Genetics Inc News
New
Atossa Gets FDA Rare Pediatric Disease Tag For (Z)-Endoxifen In McCune-Albright Syndrome
(RTTNews) - Atossa Therapeutics, Inc. (ATOS) on Monday said the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright S...
Insider Trading Fugitive Stuck in China After US Flight Ban
(Bloomberg) -- A fugitive accused of insider trading says he’s trapped in China because the US won’t let him board a plane to Boston to fight the charges against him. The Justice Department isn’...
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service
Atos IT Solutions and Services, Inc. Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service Irving, Texas, USA – March 31, 2026 –Atos, a global leader of AI-powered digita...
Notice of the Annual General Meeting to Approve the 2025 Financial Statements, Scheduled for May 22, 2026, and Changes to the Atos Board of Directors
Press Release Notice of the Annual General Meeting to Approve the 2025 Financial Statements, Scheduled for May 22, 2026, and Changes to the Atos Board of Directors Paris, France - March 27, 2026 No...
Get Atossa Genetics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
